DuoGenic StemCells Corporation (7607) Stock Statistics & Valuation Metrics
Total Valuation
DuoGenic StemCells Corporation has a market cap or net worth of TWD 438.00M. The enterprise value is ―.
- Market Cap
- TWD 438.00M
- Enterprise Value
- ―
Share Statistics
DuoGenic StemCells Corporation has 36,653,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 36,653,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
DuoGenic StemCells Corporation’s return on equity (ROE) is -0.52 and return on invested capital (ROIC) is -35.17%.
- Return on Equity (ROE)
- -0.52
- Return on Assets (ROA)
- -0.34
- Return on Invested Capital (ROIC)
- -35.17%
- Return on Capital Employed (ROCE)
- -0.50
- Revenue Per Employee
- 1.38M
- Profits Per Employee
- -1.76M
- Employee Count
- 15
- Asset Turnover
- 0.26
- Inventory Turnover
- 2.05
Valuation Ratios
The current PE Ratio of DuoGenic StemCells Corporation is -11.67. DuoGenic StemCells Corporation’s PEG ratio is -0.84.
- PE Ratio
- -11.67
- PS Ratio
- 21.17
- PB Ratio
- 10.19
- Price to FCF
- -10.02
- Price to Operating Cash Flow
- -10.27
- PEG Ratio
- -0.84
Income Statement
In the last 12 months, DuoGenic StemCells Corporation had revenue of 20.69M and earned -26.38M in profits. Earnings per share was -0.86.
- Revenue
- 20.69M
- Gross Profit
- 15.79M
- Operating Income
- -25.79M
- Pretax Income
- -26.43M
- Net Income
- -26.38M
- EBITDA
- -19.63M
- Earnings Per Share (EPS)
- -0.86
Cash Flow
In the last 12 months, operating cash flow was -41.48M and capital expenditures -2.06M, giving a free cash flow of -43.53M billion.
- Operating Cash Flow
- -41.48M
- Free Cash Flow
- -43.53M
- Free Cash Flow per Share
- -1.22
Dividends & Yields
DuoGenic StemCells Corporation pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -9.94%
- Earnings Yield
- -8.03%
Stock Price Statistics
- Beta
- 0.07
- 52-Week Price Change
- -19.53%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 60.54
- Average Volume (3m)
- 40.59K
Financial Position
DuoGenic StemCells Corporation as a current ratio of 2.24, with Debt / Equity ratio of 43.58%
- Current Ratio
- 2.24
- Quick Ratio
- 2.15
- Debt to Market Cap
- 0.04
- Net Debt to EBITDA
- 1.40
- Interest Coverage Ratio
- -28.63
Taxes
In the past 12 months, DuoGenic StemCells Corporation has paid -47.00K in taxes.
- Income Tax
- -47.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
DuoGenic StemCells Corporation EV to EBITDA ratio is -15.09, with an EV/FCF ratio of -9.92.
- EV to Sales
- 20.97
- EV to EBITDA
- -15.09
- EV to Free Cash Flow
- -9.92
- EV to Operating Cash Flow
- -10.41
Balance Sheet
DuoGenic StemCells Corporation has TWD 32.85M in cash and marketable securities with TWD 26.79M in debt, giving a net cash position of TWD 6.06M billion.
- Cash & Marketable Securities
- TWD 32.85M
- Total Debt
- TWD 26.79M
- Net Cash
- TWD 6.06M
- Net Cash Per Share
- TWD 0.17
- Tangible Book Value Per Share
- TWD 1.02
Margins
Gross margin is 68.23%, with operating margin of -166.97%, and net profit margin of -166.65%.
- Gross Margin
- 68.23%
- Operating Margin
- -166.97%
- Pretax Margin
- -166.88%
- Net Profit Margin
- -166.65%
- EBITDA Margin
- -138.96%
- EBIT Margin
- -164.21%
Analyst Forecast
The average price target for DuoGenic StemCells Corporation is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 18.63%
- EPS Growth Forecast
- 31.03%
